C
CPTx
Non-viral DNA-based in vivo CAR T therapies
About CPTx
CPTx is a preclinical-stage biotechnology company developing next-generation in vivo CAR T cell therapies. Instead of engineering T cells outside the body with viral vectors, CPTx delivers proprietary immune-quiet single-stranded DNA (ssDNA) payloads non-virally with targeting lipid nanoparticles (LNPs), so CAR T cells are generated directly in the patient.
The DNA-based platform is designed to be redosable and duration-tunable. It offers a more durable alternative to mRNA, avoids the permanent genome integration of viral vectors and supports the delivery of multiple genes. CPTx has reported preclinical efficacy data in rodents and first safety data in non-human primates, and is preparing its lead programs for first-in-human studies.
The company is advancing a pipeline of differentiated, first-in-class programs across oncology and autoimmune disease, combining expertise in DNA vector design, genetic engineering, cancer biology and immunology. It develops its own therapeutics and partners with other companies on genetic medicines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Planegg, Germany
- Employees
- 49
- Open positions
- None listed
- Dealroom signal
- 84.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Infections and Infectious Diseases, Genetics and genomics, Gene Therapy, Disease, Biotech and Pharma, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2024 | $29M | $116M | Andrej Henkler · Bayern Kapital · Stefan Oschmann · BlueYard Capital | ↗ |
| SEED✓Equity / VC | Feb 2024 | — | — | BlueYard Capital | — |
Growth signals
Latest recorded traffic for CPTx is 2.6K monthly website visits, up 160% over the last three months. CPTx's team grew 14% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
BlueYard Capital
Series A4 investors entered at this stage
SPRIN-D
Andrej Henkler
Bayern Kapital
Stefan Oschmann
Other known investors1 additional known investor
Leblon Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CPTx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CPTx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.